Cara Therapeutics(CARA) - 2025 Q4 - Annual Results

Exhibit 99.1 Tvardi Therapeutics Announces Fourth Quarter and Full-Year 2025 Results and Provides Business Update Results from healthy volunteer study of next-generation STAT3 inhibitor, TTI-109, on track for Q2 2026 Topline data from Phase 2 trial of TTI-101 in hepatocellular carcinoma (HCC) are anticipated in H2 2026 Cash runway expected to be suf icient to fund operations into Q4 2026 after clinical readouts HOUSTON, TX – March 31, 2026 - Tvardi Therapeutics, Inc. ("Tvardi") (NASDAQ: TVRD), a clinical-st ...